Bronchodilators and anti-inflammatory agents are the mainstream treatments in chronic
obstructive and pulmonary disease (COPD) and asthma. The combination of β2 adrenergic …

Background Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β 2−
agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary …

Combinations of a muscarinic receptor antagonist (MA) and a β2-adrenoceptor agonist (BA)
improve bronchodilation in COPD patients to a greater extent than drugs with either …

Bronchodilators remain the cornerstone of the treatment of airway disorders such as asthma
and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest …

Recent evidence indicates that AZD8999 (LAS190792), a novel muscarinic acetylcholine
receptor antagonist and β2-adrenoceptor agonist (MABA) in development for chronic …

Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

Beta-adrenergic receptor antagonists are currently used as first-line therapy in the treatment
of hypertension and angina pectoris, but are contraindicated or used with caution in patients …

Frequently developed after years of smoking, chronic obstructive pulmonary disease
(COPD) is characterized by progressive air outflow limitation that is not fully reversible (1, 2) …

BACKGROUND: Inhaled propranolol causes bronchoconstriction in asthmatic subjects by
an indirect mechanism which remains unclear. Inhaled frusemide has been shown to …

Background Navafenterol (AZD8871) belongs to a new class of bronchodilator, the single-
molecule muscarinic antagonist and β-agonist, developed for the treatment of COPD. This …